SCHEMBL996878

SCHEMBL996878

O=C(NCc1ccc(C(=O)Nc2ccncc2)cc1)OCc1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 3/20 0.78
POLB P06746 2/20 0.66
HDAC1 Q13547 8/20 0.65
HDAC2 Q92769 5/20 0.65
HDAC3 O15379 4/20 0.65
HDAC4 P56524 2/20 0.61
HDAC7 Q8WUI4 2/20 0.61
HDAC10 Q969S8 2/20 0.61
HDAC11 Q96DB2 2/20 0.61
HDAC8 Q9BY41 2/20 0.61
HDAC6 Q9UBN7 2/20 0.61
HDAC9 Q9UKV0 2/20 0.61
HDAC5 Q9UQL6 2/20 0.61
KDM1A O60341 1/20 0.60
CYP3A4 P08684 1/20 0.60
F3 P13726 1/20 0.60
NCOR2 Q9Y618 1/20 0.60
SCD O00767 1/20 0.57
JAK2 O60674 1/20 0.56
TYK2 P29597 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6560027 0.88 POLB (0.63) NAMPTPOLBHDAC1HDAC2HDAC3
SCHEMBL995725 0.87 NAMPT (1.00) NAMPTHDAC1HDAC2HDAC3HDAC4
SCHEMBL2790938 0.87 POLB (0.64) NAMPTPOLBHDAC1HDAC2HDAC3
SCHEMBL5465783 0.84 NAMPT (0.66) NAMPTHDAC1HDAC2HDAC3HDAC4
SCHEMBL2793871 0.83 POLB (0.59) NAMPTPOLBHDAC1HDAC2HDAC3
SCHEMBL2793874 0.83 POLB (0.59) NAMPTPOLBHDAC1HDAC2HDAC3
SCHEMBL2818520 0.82 POLB (0.58) NAMPTPOLBHDAC1HDAC2HDAC3
SCHEMBL6558160 0.82 POLB (0.58) NAMPTPOLBKDM1ACYP3A4SCD
SCHEMBL12633526 0.82 HDAC1 (0.77) NAMPTHDAC1HDAC2HDAC3HDAC4
SCHEMBL994807 0.82 NAMPT (0.66) NAMPTHDAC1HDAC2HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2456435-B1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE UNIV LELAND STANFORD JUNIOR (US) 2015-06-24 EP disclosed
US-20120225862-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE AUCKLAND UNIVSERVICES LIMITED (NZ) 2012-09-06 US disclosed
EP-2456435-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE The Board of Trustees of The Leland Stanford Junior University (US) 2012-05-30 EP disclosed
WO-2011011514-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2011-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225862-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE BRDT, NISCH, PAICS NAMPT 624/4885POLB 156/4885HDAC1 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.